INVENTIVA S.A.

Back to previous page

Identification

IVA
Name: INVENTIVA S.A.
Market: Euronext Paris
Capitalization compartment: Compartment B
Subsector: Biotechnology
Isin code: FR0013233012
Symbol: IVA

Operation

IPO Date: 15/02/2017
Issue type: Initial Public offering
IPO Price: EUR 8.50
Price range: EUR 8.50 - EUR 9.75

Company Profile

Loading... Please wait.

News

Date Title
15 Feb 2017 Inventiva lists on Euronext Paris expand

€48 million raised; market capitalisation €133 million

Paris – 15 February 2017 – Euronext today welcomed Inventiva, a biopharmaceutical company specialised in the development of new therapies, particularly for fibrotic diseases, to Compartment C of its regulated market in Paris. 

Inventiva was founded in 2012 and delivers innovative therapies that interact with nuclear receptors, transcription factors and epigenetic modulators. The company is working to open up novel breakthrough therapies for fibrotic diseases, cancers, and orphan diseases with substantial unmet medical needs. It has over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. It also owns a proprietary chemical library of over 240,000 molecules, as well as integrated biology, chemistry, ADME and pharmacology platforms. Today Inventiva has three projects in particular, all at an advanced stage, in markets targeted by big companies, with two phase IIb clinical studies for NASH[1] and systemic sclerosis—and one phase I/II study for the treatment of Maroteaux-Lamy syndrome (MPS VI).

Inventiva (ticker code: IVA) was listed through the admission to trading on 15 February 2017 of a total of 15,681,240 shares including 5,651,240 new shares issued through a Global Offering[2], after the partial exercise of the extension option and before the potential exercise of the over-allotment option.

The offering price was set at €8.50 per share. Inventiva’s market capitalisation on the day of listing was €133 million, and the transaction raised a total of €48 million.

Inventiva joins the 52 biotechnology companies already listed on Euronext markets, which together represent a total capitalisation of €13.8 billion. In just a few years Euronext has become the European benchmark for life science businesses, and promotes the segment’s visibility with its recently launched  Biotech Barometer.

At the listing ceremony, Frédéric Cren, Chairman & CEO and co-founder of Inventiva, said, “We are delighted to list in Compartment C on Euronext Paris—a key stage in our company’s development. The funding raised today will allow us to secure additional resources to finance our business and continue to expand our technology platforms, collaborations, and drug candidates. We are very proud to join Europe’s standard-setting exchange for biotechnology companies, a move that has expanded our shareholder base to both individuals and large US and European funds specialised in life sciences.”

 

[1] Non-alcoholic steatohepatitis
[2] The Global Offering was made up of a Public Offering that included an Open Price Public Offering in France and a Global Placement with institutional investors in France and other countries

About Inventiva
www.inventivapharma.com
Inventiva is a biopharmaceutical company specialised in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.
IVA337, its lead product, is an anti-fibrotic treatment with a strong action mechanism permitting the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing in parallel, a second clinical product, IVA336, which is a clinical program for the treatment of three different forms of mucopolysaccharidosis (MPS I or Hurler-Sheie syndrome, MPS II or Hunter syndrome and MPS VI also known as Maroteaux-Lamy syndrome), as well as a preclinical stage oncology portfolio.
Inventiva benefits from two partnerships with world-leading research entities such as the Institut Curie. Two strategic partnerships have also been developed with AbbVie and Boehringer Ingelheim, making Inventiva eligible for preclinical, clinical, regulatory and commercial milestone payments, in addition to royalties on the products resulting from these partnerships.
Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

15 Feb 2017 IPO Inventiva expand

Listing of Inventiva on Euronext

Frédéric Cren, Chairman and CEO and Co-Founder of Inventiva, opens the trading day in Paris.

Inventiva specializes in the research and development of therapeutic products for the treatment of Parkinson's disease, cancer, autoimmune diseases and fibrosis.
At the end of 2015, the company has a portfolio of five products, including 3 in pre-clinical development phase and 2 in clinical development.